{"id":"W2489240616","doi":"10.1182/blood.v126.23.2745.2745","title":"Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATETM)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Royal Victoria Hospital; Dalhousie University","funders":"","keywords":"Ibrutinib; Rituximab; Medicine; Waldenstrom macroglobulinemia; Macroglobulinemia; Open label; Internal medicine; Refractory (planetary science); Lymphoplasmacytic Lymphoma; Phases of clinical research; Oncology; Clinical trial; Lymphoma; Leukemia; Multiple myeloma; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003697693,0.001027062,0.001520442,0.000350428,0.0003906286,0.001155552,0.0007470801,0.000993009,0.001495165],"category_scores_gemma":[0.001507214,0.0003634,0.001712307,0.0007486666,0.0005091075,0.0007374479,0.000517291,0.002162538,0.0004422054],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009984619,"about_ca_system_score_gemma":0.001072758,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001207826,"about_ca_topic_score_gemma":0.003685039,"domain_scores_codex":[0.9990665,0.0004808263,0.00009245865,0.0001177372,0.000106739,0.0001358343],"domain_scores_gemma":[0.9988791,0.0002443787,0.0002897111,0.0001001367,0.0001305766,0.0003559864],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6329637,0.03722989,0.04907633,0.002881866,0.01045328,0.0004967311,0.00103863,0.002830624,0.04343454,0.0003343485,0.01173722,0.2075229],"study_design_scores_gemma":[0.4733182,0.3117705,0.1785114,0.0005048611,0.008961676,0.001189487,0.0003879423,0.001771409,0.006633975,0.0003715353,0.01646336,0.0001154168],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9783652,0.01230993,0.0007509763,0.0006010229,0.0001108275,0.001856594,0.003339204,0.00006383329,0.002602423],"genre_scores_gemma":[0.9789164,0.005605741,0.001978589,0.001710538,0.0002961138,0.002111466,0.008469686,0.00003689249,0.0008746729],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003697693,"threshold_uncertainty_score":0.01955551,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09222182345165915,"score_gpt":0.4035739745569185,"score_spread":0.3113521511052594,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}